Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference
MENLO PARK, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will present at the upcoming Bank of America Healthcare Conference, in Las Vegas, NV.
加利福尼亞州門洛帕克，2024年5月7日（GLOBE NEWSWIRE）——專注於開發和商業化提高護理標準的創新介入技術的眼部護理技術公司Sight Sciences, Inc.（納斯達克股票代碼：SGHT）（“Sight Sciences” 或 “公司”）今天宣佈，它將出席即將在內華達州拉斯維加斯舉行的美國銀行醫療保健會議。
Sight Sciences' management is scheduled to present on Tuesday, May 14, 2024, at 8:15 am PT / 11:15 am ET. Interested parties may access a live and archived webcast of the fireside chat on the "Investors" section of the company's website at: investors.sightsciences.com.
Sight Sciences的管理層定於太平洋時間2024年5月14日星期二上午8點15分/美國東部時間上午11點15分發表講話。有興趣的人士可以在公司網站的 “投資者” 欄目上觀看爐邊談話的直播和存檔網絡直播，網址爲：investors.sightsciences.com。
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional technologies intended to transform care and improve patients' lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world's most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company's OMNI Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm's canal and the cutting of trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world's leading cause of irreversible blindness. The Company's TearCare System technology is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction ("MGD") when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company's SION Surgical Instrument is a manually operated device available in the United States to be used in ophthalmic surgical procedures to excise trabecular meshwork.
關於視覺科學
Sight Sciences是一家眼部護理技術公司，專注於開發和商業化旨在改變護理和改善患者生活的創新和介入技術。Sight Sciences使用微創或非侵入性方法來針對世界上最流行的眼病的根本原因，旨在創建更有效的治療模式，以增強患者護理並取代傳統的過時方法。該公司的OMNI Surgical System是一項無需植入的青光眼手術技術（i）在美國指示用於降低原發性開角型青光眼成年患者的眼壓；（ii）CE標誌，用於對施萊姆管進行導管插入和腔內粘度擴張，切斷小梁網以降低開角型青光眼成年患者的眼內壓力。青光眼是世界上導致不可逆失明的主要原因。該公司的TearCare System技術在美國獲得510（k）許可，用於對因瞼板腺功能障礙（“MGD”）導致的蒸發性乾眼病的成年患者進行局部熱療，當與瞼板腺的手動表達結合使用時，醫生可以清除腺體阻塞，以解決乾眼病的主要原因。該公司的SION手術器械是一種手動操作的設備，可在美國上市，用於眼科外科手術，以切除小梁網。
For more information, visit
欲了解更多信息，請訪問
Sight Sciences and TearCare are trademarks of Sight Sciences registered in the United States. OMNI, OMNI ERGO, and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.
Sight Sciences 和 TearCare 是 Sight Sciences 在美國註冊的商標。OMNI、OMNI ERGO和SION是Sight Sciences在美國、歐盟和其他地區註冊的商標。
2024 Sight Sciences. All rights reserved.
2024 年視覺科學。版權所有。
Media contact:
pr@SightSciences.com
媒體聯繫人：
pr@SightSciences.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
投資者聯繫人：
菲利普泰勒
吉爾馬丁集團
415.937.5406
Investor.Relations@Sightsciences.com
譯文內容由第三人軟體翻譯。